Actavis Generics was founded in 1983 and was formerly known as Watson Pharmaceuticals and Actavis, plc before the acquisition of Allergan, Inc.. Actavis Generics is a global pharmaceutical company that focuses on developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter (OTC) drugs. Their global headquarters are located in Dublin, Ireland and their administrative headquarters are in New Jersey, U.S.
Actavis sells brand products by way of six franchises in therapeutic areas such as: Aesthetics/Dermatology/Plastic Surgery; Neurosciences/CNS; Eye Care; Women’s Health and Urology; GI and Cystic Fibrosis; and Cardiovascular Disease and Infectious Disease. Some of their products include Botox, Namenda, Restasis, Linzess, Bystolic, Juvederm, Latisse, Lo Loestrin FE, Estrace, Teflaro, Dalvance, Ozurdex, Optive, Natrelle, Vibryd, Liletta, Saphris, Enablex, Accetonel, Androderm and Gelnique.
Actavis has high ratings in all global markets and develops and out-licenses generic pharmaceutical products outside the U.S. by way of its Medis third-party business. With more than 300 customers around the world, Medis has more than 200 products to offer.
Actavis also develops biosimilars products in oncology as well as other therapeutic areas. Biosimilar products are biological products that have been approved by the FDA to be similar to another biological product meaning that there is no difference in safety and effectiveness from the original product.
This pharmaceutical company to date has 40 manufacturing plants spread around the globe and are leading in modified release products, solid oral dosages, transdermals, semi-solids, liquids and injectables. They have facilities in Australia, Belgium, Brazil, Bulgaria, Canada, China, France, Germany, Greece, Iceland, India, Indonesia, Ireland, Northern-Ireland, Italy, Malta, Puerto Rico, Romania, Singapore, Serbia, Thailand, UK and USA.
In 2015, Actavis changed its name to Allergan, however Actavis will continue to operate under its old name in the U.S. and Canada. By mid 2015, Allergan announced that it would sell its Generic division to Teva Pharmaceuticals. The Generics division was sold for 40.5 billion dollars.
Actavis, plc has 27 global R&D facilities focusing on the development of modified release products, solid oral dosages, transdermal medicines, semi-solids, liquids and injectables around the world.
The company’s R&D facilities are located in Belgium, Bulgaria, China, France, Iceland, Italy, India, Indonesia, Ireland, Japan, Northern Ireland, Romania, UK and USA.
With acquisition of Actavis/Allergan Generic division, Teva continue to evaluate and pursue opportunities that will strengthen their diversification and bring even better value to patients and healthcare providers globally. This acquisition brings together two leading generic businesses that have complementary strengths, brands and business cultures. The melding of these two companies provides for the richest product pipeline and no doubt will continue to lead the way with complementary technologies offering even better products than any other generic company.